New pledge underscores confidence in early detection, supported by the Avantect® Liquid Biopsy and HLI’s Executive Health Program
SOUTH SAN FRANCISCO, Calif., July 17, 2025 /PRNewswire/ — Human Longevity, Inc. (HLI), a global leader in precision medicine and proactive healthcare, today announced the expansion of its $1 million cancer prevention pledge — now focused on late-stage ovarian cancer. Reflecting HLI’s unwavering belief in early detection and the power of precision diagnostics, this bold initiative will offer up to $1 million in treatment and clinical support for any qualified member diagnosed with late-stage ovarian cancer while actively participating in HLI’s Executive Health Program or affiliated 100+ Longevity Programs.
Pioneering Early Detection with Avantect® Liquid Biopsy
Through its Executive Health Program, Human Longevity has screened over 10,000 members using a comprehensive, AI-driven platform that integrates genomics, imaging, and biomarkers. This ovarian cancer prevention initiative will now incorporate the Avantect® Ovarian Cancer Liquid Biopsy — the first clinically validated blood test to detect early-stage ovarian cancer with high negative predictive value (NPV). By identifying tumor-derived cell-free DNA signals, the Avantect® test enhances HLI’s multi-modal detection strategy.
This precision strategy includes:
- Whole genome sequencing, including BRCA1/2 and other hereditary cancer-related genes
- Whole-body MRI with dedicated pelvic imaging
- Avantect® Ovarian Cancer Liquid Biopsy
- Multi-cancer early detection (MCED) blood tests
- Continuous symptom and biomarker monitoring
This integrated approach—offered exclusively through HLI’s Executive Health Program—allows Human Longevity to detect ovarian cancer earlier and with greater confidence, empowering women with better outcomes.
How the Initiative Works
Eligible participants must be continuously enrolled in the Executive Health Program or 100+ Longevity Programs, and must complete annual ovarian cancer-specific screenings, including the Avantect® liquid biopsy, as part of their clinical protocol. If a participating member is diagnosed with late-stage ovarian cancer during active membership, HLI will provide up to $1 million in treatment support, clinical navigation, and consultation with top gynecologic oncology experts.
“Prevention is the future of medicine,” said Dr. Wei-Wu He, Executive Chairman of Human Longevity, Inc. “With the Avantect® liquid biopsy in addition to our Executive Health Program, we are further strengthening our ability to catch cancer before it’s too late. And in the rare case we miss something, our pledge ensures our members receive the best care in the world.”
Leading the Future of Women’s Health
Ovarian cancer is among the most lethal gynecologic cancers due to its late-stage diagnoses. By combining cutting-edge tools like Avantect®, advanced imaging, and AI-enabled analytics within the Executive Health Program, Human Longevity is redefining what’s possible in women’s health and cancer prevention.
This pledge is more than a financial commitment—it’s a call to action for precision prevention. It reflects HLI’s mission to radically shift healthcare from reactive to proactive, ensuring its members benefit from the most advanced tools available.
About Human Longevity, Inc.
Human Longevity, Inc. is a biotechnology company at the forefront of integrating genomics, AI, and multimodal diagnostics to extend human healthspan. Through its flagship Executive Health Program and 100+ Longevity Programs, HLI delivers comprehensive, data-driven evaluations aimed at identifying and preventing disease long before symptoms arise.
To learn more or how to enroll, visit www.humanlongevity.com or https://www.humanlongevity.com/1movarian/.
Media Contact:
[email protected]
www.humanlongevity.com
SOURCE Human Longevity, Inc.
